

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**(1) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION;
AND
(2) ELECTION, RE-ELECTION,
APPOINTMENTS AND RE-APPOINTMENTS RELATING
TO THE BOARD, BOARD COMMITTEES AND
SENIOR MANAGEMENT**

The board of directors (the “**Board**”) of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that on May 21, 2020, at the first meeting of the second session of the Board, the Board has resolved and approved (i) certain proposed amendments to the articles of association of the Company (the “**Articles of Association**”); and (ii) the election, re-election, appointments and re-appointments relating to the Board, Board committees and senior management of the Company, all with effect from May 21, 2020, following the election of the second session of the Board on May 15, 2020. Details of these resolutions are set forth below.

(1) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board proposes to make relevant amendments to the Articles of Association in connection with the establishment of the role of a vice chairman of the Board as follows:

Original Articles	Amended Articles
<p>Article 98 General meetings shall be convened by the Board. General meetings shall be presided over by the chairman. Where the chairman cannot or does not fulfil the duty thereof, more than half of the directors may jointly elect a director to preside over the meeting.</p> <p>.....</p>	<p>Article 98 General meetings shall be convened by the Board. General meetings shall be presided over by the chairman. Where the chairman cannot or does not fulfil the duty thereof, <u>the vice chairman shall preside over the meeting; where the vice chairman cannot or does not fulfil the duty thereof</u>, more than half of the directors may jointly elect a director to preside over the meeting.</p> <p>.....</p>
<p>Article 158 The Board shall comprise 12 directors, including 5 independent directors.</p> <p>The Board shall have one chairman.</p> <p>.....</p>	<p>Article 158 The Board shall comprise 12 directors, including 5 independent directors.</p> <p>The Board shall have one chairman., <u>and may have one vice chairman. The chairman and vice chairman shall be elected by more than half of the directors of the Board.</u></p> <p>.....</p>
<p>Article 169 If the chairman is unable or fails to perform his duties, a director shall be elected jointly by more than half of the directors to perform such duties.</p>	<p>Article 169 If the chairman is unable or fails to perform his duties, <u>the vice chairman shall perform such duties; if the vice chairman is unable or fails to perform his duties</u>, a director shall be elected jointly by more than half of the directors to perform such duties.</p>

Save for the proposed amendments, other articles of the Articles of Association shall remain unchanged.

The proposed amendments to the Articles of Association shall be subject to the approval by resolution of shareholders of the Company (the “**Shareholders**”) at next Shareholders’ meetings and all the necessary approval, authorization, filing and/or registration from the relevant governmental or regulatory authorities of the People’s Republic of China (the “**PRC**”).

(2) ELECTION, RE-ELECTION, APPOINTMENTS AND RE-APPOINTMENTS RELATING TO THE BOARD, BOARD COMMITTEES AND SENIOR MANAGEMENT

Following and coterminous with the establishment of the second session of the Board on May 15, 2020, the Board has resolved to make the following appointments election, re-election, appointments and re-appointments relating to the Board, Board committees and senior management of the Company, the terms of which will all take effect from May 21, 2020 until the expiry of the term of the second session of the Board.

(i) Re-election of the chairman to the Board

The Board has resolved and approved the re-election of Dr. Ge Li (李革) as the chairman to the second session of the Board for a term of three years with effect from May 21, 2020 until the expiry of the term of the second session of the Board.

Biographical details of Dr. Ge Li are set out in the 2019 annual report of the Company.

(ii) Re-appointment of manager of the Company (president and chief executive officer)

The Board has resolved and approved the re-appointment of Dr. Ge Li as the manager of the Company (president and chief executive officer) with effect from May 21, 2020 until the expiry of the term of the second session of the Board.

(iii) Election of vice chairman to the Board

According to the Company Law of the PRC, a joint stock limited company may have a vice chairman which shall be elected by more than half of the directors by the board of directors.

In order to further improve the corporate governance of the Company, the Board has resolved and approved the election of Mr. Edward Hu (胡正國) as the vice chairman to the second session of the Board for a term of three years with effect from May 21, 2020 until the expiry of the term of the second session of the Board.

Biographical details of Mr. Edward Hu are set out in the 2019 annual report of the Company.

(iv) Appointment of global chief investment officer

The Board has resolved and approved the appointment of Mr. Edward Hu as the global chief investment officer of the Company to lead the Group's global investment, mergers and acquisitions, and new business development with effect from May 21, 2020 until the expiry of the term of the second session of the Board.

(v) Appointment of co-chief executive officer

The Board has resolved and approved the appointment of Dr. Steve Qing Yang (楊青) as the co-chief executive officer of the Company with effect from May 21, 2020 until the expiry of the term of the second session of the Board.

Biographical details of Dr. Steve Qing Yang are set out in the circular of the Company dated March 31, 2020.

Pursuant to Rule 13.51(2) of the of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), as at the date of this announcement, except for 205,720 domestic shares of the Company (the “**A Shares**”) (comprising 169,432 restricted A Shares) granted to Dr. Steve Qing Yang, Dr. Yang does not hold any shares of the Company nor any other interests in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

(vi) Re-appointment of vice presidents

The Board has resolved and approved the re-appointments of Dr. Minzhang Chen (陳民章), Dr. Shuhui Chen (陳曙輝), Mr. Zhaohui Zhang (張朝暉) and Dr. Ning Zhao (趙寧) as the vice presidents of the Company with effect from May 21, 2020 until the expiry of the term of the second session of the Board.

Biographical details of Dr. Minzhang Chen, Dr. Shuhui Chen, Mr. Zhaohui Zhang and Dr. Ning Zhao are set out in the 2019 annual report of the Company.

(vii) Re-appointment of chief financial officer

The Board has resolved and approved the re-appointment of Mr. Ellis Bih-Hsin Chu (朱璧辛) as the chief financial officer of the Company with effect from May 21, 2020 until the expiry of the term of the second session of the Board.

Biographical details of Mr. Ellis Bih-Hsin Chu are set out in the 2019 annual report of the Company.

(viii) Re-appointment of Board secretary

The Board has resolved and approved the re-appointment of Mr. Chi Yao (姚馳) as the Board secretary of the Company with effect from May 21, 2020 until the expiry of the term of the second session of the Board.

Biographical details of Mr. Chi Yao are set out in the 2019 annual report of the Company.

(ix) Re-appointment of members of Board committees

The Board has resolved and approved the re-appointments of the various members to the four Board committees as follow:

Audit Committee

Dr. Hetong Lou (*Chairperson*)

Mr. Xiaotong Zhang

Ms. Yan Liu

Remuneration and Appraisal Committee

Ms. Yan Liu (*Chairperson*)

Dr. Hetong Lou

Dr. Ning Zhao

Strategy Committee

Dr. Ge Li (*Chairperson*)

Mr. Edward Hu

Mr. Xiaomeng Tong

Dr. Yibing Wu

Dr. Jiangnan Cai

Nomination Committee

Dr. Jiangnan Cai (*Chairperson*)

Ms. Yan Liu

Dr. Ge Li

Save as disclosed above, there are no other matters concerning the abovementioned election, re-election, appointments and re-appointments relating to the Board, Board committees and senior management of the Company that need to be brought to the attention of the Shareholders and The Stock Exchange of Hong Kong Limited, and there are no other matters which shall be disclosed election, re-election, appointments and pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, May 21, 2020

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*